Science and Research

A prospective, randomized, open label Phase 2 clinical trial to evaluate superiority of anti-SARS-CoV-2 convalescent plasma versus standard-of-care in hospitalized pa-tients with mild COVID-19

To assess the efficacy of convalescent plasma for the treatment of hospitalized patients with mild COVID-19 infection

Study details
Study-ID: 2020-001936-86
Study-ID: 2020-001936-86
DZL Disease Area: PALI
DZL Disease Area: PALI
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: BREATH
DZL Participating Sites: BREATH
Start Date: 17.11.2020
Completion Date: 01.11.2021
Status: Closed
Status: Closed
DZL recruiting center


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.